At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
LXRX Lexicon Pharmaceuticals
Closed 08-17 16:00:00 EDT
2.34
+0.02
+0.86%
盘后2.35
+0.01+0.43%
19:34 EDT
High2.39Low2.29Vol3.53M
Open2.31D1 Closing2.32Amplitude4.33%
Mkt Cap1.04BTradable Cap515.77MTotal Shares444.00M
T/O8.24MT/O Rate1.60%Tradable Shares220.42M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Quantum BioPharma Receives United States FDA Clearance To Proceed with Lucid-MS Phase 2 Trial in Progressive Multiple Sclerosis:
GlobeNewswire  ·  08-10
Quantum BioPharma Receives United States FDA Clearance To Proceed with Lucid-MS Phase 2 Trial in Progressive Multiple Sclerosis:
Lexicon Pharmaceuticals (LXRX) Receives a Buy from Piper Sandler
TIPRANKS  ·  08-07
Lexicon Pharmaceuticals (LXRX) Receives a Buy from Piper Sandler
Lexicon Pharmaceuticals - to Offer up to 1,257,856 Shares of Common Stock Issuable to Selling Stockholders - SEC Filing
THOMSON REUTERS  ·  08-07
Lexicon Pharmaceuticals - to Offer up to 1,257,856 Shares of Common Stock Issuable to Selling Stockholders - SEC Filing
Lexicon Pharmaceuticals Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
Reuters  ·  08-06
Lexicon Pharmaceuticals Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
Earnings Flash (LXRX) Lexicon Pharmaceuticals Posts Q2 Loss $0.07 a Share, vs. FactSet Est of $0.05 Loss
MT Newswires Live  ·  08-06
Earnings Flash (LXRX) Lexicon Pharmaceuticals Posts Q2 Loss $0.07 a Share, vs. FactSet Est of $0.05 Loss
Lexicon Pharmaceuticals Posts Q2 Net Loss
Reuters  ·  08-06
Lexicon Pharmaceuticals Posts Q2 Net Loss
Lexicon Pharmaceuticals Q2 EPS $(0.07) Misses $(0.05) Estimate, Sales $692.000K Miss $3.998M Estimate
Benzinga Earnings  ·  08-06
Lexicon Pharmaceuticals Q2 EPS $(0.07) Misses $(0.05) Estimate, Sales $692.000K Miss $3.998M Estimate
Lexicon Q2 FY26 Net Loss Widens to $31.8 Million; Revenue Drops to $0.7 Million
Reuters  ·  08-06
Lexicon Q2 FY26 Net Loss Widens to $31.8 Million; Revenue Drops to $0.7 Million
Lexicon Pharmaceuticals Q2 Basic EPS USD -0.07
THOMSON REUTERS  ·  08-06
Lexicon Pharmaceuticals Q2 Basic EPS USD -0.07
Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
GlobeNewswire  ·  08-06
Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
Lexicon Pharmaceuticals Inc Expected to Post a Loss of 5 Cents a Share - Earnings Preview
Reuters  ·  08-04
Lexicon Pharmaceuticals Inc Expected to Post a Loss of 5 Cents a Share - Earnings Preview
Lexicon Pharmaceuticals Inc Expected to Post a Loss of 5 Cents a Share - Earnings Preview
Reuters  ·  07-31
Lexicon Pharmaceuticals Inc Expected to Post a Loss of 5 Cents a Share - Earnings Preview
Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026
GlobeNewswire  ·  07-30
Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026
Lexicon Pharmaceuticals: Advancing Cardiometabolic Pipeline and Phase 3 HCM Data Support Unchanged $6 Price Target and Buy Rating
TIPRANKS  ·  07-27
Lexicon Pharmaceuticals: Advancing Cardiometabolic Pipeline and Phase 3 HCM Data Support Unchanged $6 Price Target and Buy Rating
Lexicon completes enrollment in SONATA-HCM study
TIPRANKS  ·  07-27
Lexicon completes enrollment in SONATA-HCM study
Lexicon Pharmaceuticals Completes Enrollment in Trial of Potential Hypertrophic Cardiomyopathy Treatment
MT Newswires Live  ·  07-27
Lexicon Pharmaceuticals Completes Enrollment in Trial of Potential Hypertrophic Cardiomyopathy Treatment
Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 Sonata-Hcm Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (Hcm)
Reuters  ·  07-27
Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 Sonata-Hcm Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (Hcm)
Lexicon Pharmaceuticals - Topline Results for Sonata-HCM Trial Anticipated in Q1 2027
THOMSON REUTERS  ·  07-27
Lexicon Pharmaceuticals - Topline Results for Sonata-HCM Trial Anticipated in Q1 2027
How Lexicon Pharma’s Expanded Russell Index Footprint Shapes Its Pipeline Narrative for Investors (LXRX)
Simply Wall St.  ·  07-02
How Lexicon Pharma’s Expanded Russell Index Footprint Shapes Its Pipeline Narrative for Investors (LXRX)
Lexicon presents new sotagliflozin Type 1 diabetes subgroup analysis at ADA 2026 sessions
Reuters  ·  06-03
Lexicon presents new sotagliflozin Type 1 diabetes subgroup analysis at ADA 2026 sessions

Introduction

Company Name.
Lexicon Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Issue price:
--